Longeveron Schedules 2020 Fiscal Year End Business Update Conference Call

Rhea-AI Summary

Longeveron (NASDAQ: LGVN), a clinical stage biotechnology company, announced a conference call on March 30, 2021, at 8:30 a.m. ET to discuss its fiscal 2020 financial results and provide a business update. The call will be accessible via telephone and a webcast. Longeveron is focused on developing cellular therapies for chronic aging-related and life-threatening conditions, with its lead product, LOMECEL-B™, targeting multiple indications including Aging Frailty and Alzheimer’s disease. An audio replay of the call will be available until April 6, 2021.

Positive

• Company is advancing its lead product LOMECEL-B™ in Phase 1 and 2 clinical trials targeting critical conditions.
• Commencement of fiscal 2020 financial results discussion may indicate transparency and a commitment to shareholder communication.

Negative

• None.

MIAMI, March 26, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced it will host a conference call at 8:30 a.m. Eastern Time on Tuesday, March 30, 2021 to discuss its fiscal 2020 financial results and provide a business update.

The conference call will be available via telephone by dialing toll free 1-855-979-6654 for U.S. callers or +44 20-3936-2999 for international callers and using entry code 094408. You may also pre-register for the event. A webcast of the call may be accessed here or on the Company’s website at https://www.longeveron.com/.

An audio replay of the of the call will be available through April 6, 2021 and can be accessed here and by entering the access code: 40245, and will remain online for one year through March 30, 2022.         

About Longeveron

Longeveron is a clinical stage biotechnology company developing cellular therapies for specific aging-related and life-threatening conditions. The Company’s lead investigational product is the LOMECEL-B™ cell-based therapy product (“Lomecel-B”), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young, healthy adult donors. Longeveron believes that by using the same cells that promote tissue repair, organ maintenance, and immune system function, it can develop safe and effective therapies for some of the most difficult disorders associated with the aging process and other medical disorders. Longeveron is currently sponsoring Phase 1 and 2 clinical trials in the following indications: Aging Frailty, Alzheimer’s disease, the Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). The Company’s mission is to advance Lomecel-B and other cell-based product candidates into pivotal Phase 3 trials, with the goal of achieving regulatory approvals, subsequent commercialization and broad use by the healthcare community. Additional information about the Company is available at www.longeveron.com.

Contact:
Crescendo Communications, LLC
Tel: 212-671-1020
Email: lgvn@crescendo-ir.com 

FAQ

What is the date of Longeveron's conference call regarding fiscal 2020 results?

Longeveron's conference call will take place on March 30, 2021, at 8:30 a.m. ET.

How can I access Longeveron's conference call?

You can access the conference call by dialing 1-855-979-6654 for U.S. callers or +44 20-3936-2999 for international callers.

What is Longeveron's lead product?

Longeveron's lead product is LOMECEL-B™, a cell-based therapy targeting aging-related and life-threatening conditions.

What clinical trials is Longeveron sponsoring?

Longeveron is currently sponsoring Phase 1 and 2 clinical trials for Aging Frailty, Alzheimer’s disease, Metabolic Syndrome, ARDS, and HLHS.

When is the audio replay of the conference call available until?

The audio replay of the conference call will be available until April 6, 2021.